A GLASGOW scientist is set to take a leading role in a 'first of its kind' clinical trial hoping to help people with lung cancer.
The UK trial has been awarded £900,000 from Cancer Research UK to help make treatment of Scotland's most common cancer more effective.
Professor Anthony Chalmers, from the University of Glasgow, is among the group of scientists heading the trial.
READ MORE: Homelessness charity The Marie Trust could lose premises over lease row with The Wayfair Club
They are set to investigated the use of a number of new drugs alongside radiotherapy to improve the survival rate of patients with advanced non-small cell lung cancer.
The trial will test drugs which prevent cancer cells from repairing their DNA after radiotherapy destroys it - often referring to as ‘DNA damage response inhibitors’, or DDRi.
Co-investigator on the trial, Anthony Chalmers, said: "In the CONCORDE trial we will be able to test several of the most promising DDRi, and find out which have potential to improve outcomes for lung cancer patients, and which might cause additional side effects.”
A nationwide network will begin recruiting patients for the trial in December.
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here